• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

INmune Bio Inc. - Common stock (NQ:INMB)

1.290 -0.050 (-3.73%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 607,989
Open 1.360
Bid (Size) 1.290 (100)
Ask (Size) 1.330 (600)
Prev. Close 1.340
Today's Range 1.260 - 1.370
52wk Range 1.210 - 11.64
Shares Outstanding 17,703,692
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer’s Webinar
February 23, 2026
Webinar on February 27 at 9:30 AM ET will have key opinion leaders discuss recent and upcoming clinical development of XPro1595 
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB
February 19, 2026
From INmune Bio, Inc.
Via GlobeNewswire

Performance

YTD
-16.2%
-16.2%
1 Month
-19.9%
-19.9%
3 Month
-25.9%
-25.9%
6 Month
-36.5%
-36.5%
1 Year
-83.6%
-83.6%

More News

Read More
INMB Stock Rises Pre-Market – What Did The FDA Say About Its Alzheimer’s Trial? ↗
February 12, 2026
Via Stocktwits
News headline image
INmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Early Alzheimer’s Disease
February 12, 2026
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB
February 10, 2026
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For October 30, 2025 ↗
October 30, 2025
Via Benzinga
News headline image
Earnings Scheduled For August 7, 2025 ↗
August 07, 2025
Via Benzinga
News headline image
INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives
January 27, 2026
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio’s CORDStrom™ Platform
December 05, 2025
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595’s Evidence Base in High-Inflammation Alzheimer's Patients
December 01, 2025
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference
November 18, 2025
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INMUNE BIO INC (NASDAQ:INMB) Reports Narrower-Than-Expected Q3 2025 Loss ↗
October 30, 2025
Via Chartmill
News headline image
INmune Bio Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on Thursday, October 30, 2025
October 23, 2025
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025
October 14, 2025
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Announces Submission of Phase 2 MINDFuL Trial Results in Alzheimer’s Disease to npj Dementia, a Nature Portfolio Journal
September 29, 2025
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Announces Successful Completion of First Commercial Pilot-Scale Manufacturing Run of CORDStrom™ at CGT Catapult
September 15, 2025
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio (INMB) Q2 Loss Widens 110% ↗
August 07, 2025
Via The Motley Fool
Topics Intellectual Property
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
August 07, 2025
Via Benzinga
News headline image
What's going on in today's pre-market session ↗
August 04, 2025
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
August 04, 2025
Via Benzinga
News headline image
INmune Bio’s CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment
August 04, 2025
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th
July 31, 2025
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro™ Presented at the Alzheimer’s Association International Conference
July 29, 2025
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
Why Celcuity Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket ↗
July 28, 2025
Via Benzinga
News headline image
INmune Bio Rebounds Sharply During After Hours Trading: What's Driving the Surge? ↗
July 28, 2025
Via Benzinga

Frequently Asked Questions

Is INmune Bio Inc. - Common stock publicly traded?
Yes, INmune Bio Inc. - Common stock is publicly traded.
What exchange does INmune Bio Inc. - Common stock trade on?
INmune Bio Inc. - Common stock trades on the Nasdaq Stock Market
What is the ticker symbol for INmune Bio Inc. - Common stock?
The ticker symbol for INmune Bio Inc. - Common stock is INMB on the Nasdaq Stock Market
What is the current price of INmune Bio Inc. - Common stock?
The current price of INmune Bio Inc. - Common stock is 1.290
When was INmune Bio Inc. - Common stock last traded?
The last trade of INmune Bio Inc. - Common stock was at 02/27/26 04:00 PM ET
What is the market capitalization of INmune Bio Inc. - Common stock?
The market capitalization of INmune Bio Inc. - Common stock is 22.84M
How many shares of INmune Bio Inc. - Common stock are outstanding?
INmune Bio Inc. - Common stock has 23M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap